论文部分内容阅读
随着对肿瘤发病机制及其生物学行为的深入研究,分子靶向治疗成为目前治疗非小细胞肺癌(non-small celllung cancer,NSCLC)最具前景的研究领域。其中表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosinekinase inhibitor,EGFR-TKI)可延长患者无进展生存期并明显提高患者生活质量,然而耐药已成为影响该类药物临床应用的最大障碍。因此对EGFR-TKI耐药机制的研究已成为关注的热点。现已发现其耐药可能与受体突变、细胞内信号转导相关蛋白、EGFR以外的TK受体介导的通路活化等有关。文中就NSCLC对EGFR-TKI耐药机制的最新研究进展进行综述。
With the in-depth study on the pathogenesis of tumor and its biological behavior, molecular targeted therapy has become the most promising research field in the treatment of non-small cell lung cancer (NSCLC). Among them epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) can prolong the progression-free survival of patients and significantly improve the quality of life of patients, however, drug resistance has become the clinical application of these drugs The biggest obstacle. Therefore, the research on the mechanism of EGFR-TKI resistance has become a hot topic. It has been found that the drug resistance may be related to receptor mutation, intracellular signal transduction related proteins, TK receptor-mediated pathway activation other than EGFR. This review summarizes the latest research progress on the mechanism of EGFR-TKI resistance in NSCLC.